Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutikizumab - AbbVie

Next Previous
Drug Profile

Lutikizumab - AbbVie

Alternative Names: ABT-981

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie
  • Class Anti-inflammatories; Bispecific antibodies; Immunoglobulins; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hidradenitis suppurativa
  • Phase II Atopic dermatitis; Crohn's disease; Psoriatic arthritis; Ulcerative colitis
  • Discontinued Osteoarthritis

Most Recent Events

  • 06 Jun 2025 Xijing Hospital plans a phase II trial for Triple negative breast cancer (first line therapy, neoadjuvant therapy) in June 2025 (NCT07007780)
  • 15 May 2025 AbbVie plans a phase II trial for Rheumatoid Arthritis (Treatment experienced) in June 2025 (SC, Injection) (NCT06972446)
  • 27 Apr 2025 Phase-II clinical trials in Psoriatic arthritis (Combination therapy, Treatment-resistant) in USA (SC) (NCT06865105)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top